CN112717130A - 一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 - Google Patents
一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 Download PDFInfo
- Publication number
- CN112717130A CN112717130A CN202110024726.9A CN202110024726A CN112717130A CN 112717130 A CN112717130 A CN 112717130A CN 202110024726 A CN202110024726 A CN 202110024726A CN 112717130 A CN112717130 A CN 112717130A
- Authority
- CN
- China
- Prior art keywords
- aupd
- core
- nanosphere
- shell
- radiosensitizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002077 nanosphere Substances 0.000 title claims abstract description 98
- 239000011258 core-shell material Substances 0.000 title claims abstract description 76
- 239000002534 radiation-sensitizing agent Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000008685 targeting Effects 0.000 title claims description 9
- 239000010931 gold Substances 0.000 claims abstract description 38
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229910052737 gold Inorganic materials 0.000 claims abstract description 33
- 239000012528 membrane Substances 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 21
- 239000002244 precipitate Substances 0.000 claims description 15
- 229960005070 ascorbic acid Drugs 0.000 claims description 11
- 235000010323 ascorbic acid Nutrition 0.000 claims description 11
- 239000011668 ascorbic acid Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 229910003244 Na2PdCl4 Inorganic materials 0.000 claims description 7
- 239000010409 thin film Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 3
- 230000000284 resting effect Effects 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 16
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 15
- 239000001301 oxygen Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 13
- 239000002120 nanofilm Substances 0.000 abstract description 7
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000000637 radiosensitizating effect Effects 0.000 abstract description 4
- 238000002428 photodynamic therapy Methods 0.000 abstract description 2
- 230000004083 survival effect Effects 0.000 abstract description 2
- 239000002105 nanoparticle Substances 0.000 description 24
- 210000001772 blood platelet Anatomy 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 11
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 206010021143 Hypoxia Diseases 0.000 description 8
- 230000007954 hypoxia Effects 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 239000010408 film Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000012798 spherical particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000002086 nanomaterial Substances 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000006557 surface reaction Methods 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 102100028292 Aladin Human genes 0.000 description 1
- 101710065039 Aladin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229910003771 Gold(I) chloride Inorganic materials 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QZPSXPBJTPJTSZ-UHFFFAOYSA-N aqua regia Chemical compound Cl.O[N+]([O-])=O QZPSXPBJTPJTSZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- FDWREHZXQUYJFJ-UHFFFAOYSA-M gold monochloride Chemical compound [Cl-].[Au+] FDWREHZXQUYJFJ-UHFFFAOYSA-M 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009616 inductively coupled plasma Methods 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- ABKQFSYGIHQQLS-UHFFFAOYSA-J sodium tetrachloropalladate Chemical compound [Na+].[Na+].Cl[Pd+2](Cl)(Cl)Cl ABKQFSYGIHQQLS-UHFFFAOYSA-J 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/06—Metallic powder characterised by the shape of the particles
- B22F1/065—Spherical particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/07—Metallic powder characterised by particles having a nanoscale microstructure
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/17—Metallic particles coated with metal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Composite Materials (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Botany (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110024726.9A CN112717130A (zh) | 2021-01-08 | 2021-01-08 | 一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110024726.9A CN112717130A (zh) | 2021-01-08 | 2021-01-08 | 一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112717130A true CN112717130A (zh) | 2021-04-30 |
Family
ID=75589813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110024726.9A Pending CN112717130A (zh) | 2021-01-08 | 2021-01-08 | 一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112717130A (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011156952A1 (zh) * | 2010-06-13 | 2011-12-22 | 海洋王照明科技股份有限公司 | 核壳型磁性合金纳米颗粒的制备方法 |
US20160271274A1 (en) * | 2013-11-07 | 2016-09-22 | The Johns Hopkins University | Synthesis and use of targeted radiation enhancing iron oxide-silica-gold nanoshells for imaging and treatment of cancer |
-
2021
- 2021-01-08 CN CN202110024726.9A patent/CN112717130A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011156952A1 (zh) * | 2010-06-13 | 2011-12-22 | 海洋王照明科技股份有限公司 | 核壳型磁性合金纳米颗粒的制备方法 |
US20160271274A1 (en) * | 2013-11-07 | 2016-09-22 | The Johns Hopkins University | Synthesis and use of targeted radiation enhancing iron oxide-silica-gold nanoshells for imaging and treatment of cancer |
Non-Patent Citations (4)
Title |
---|
CUIXIA BI,ET AL: ""Understanding the effect of ultrathin AuPd alloy shells of irregularly shaped Au@AuPd nanoparticles with high-index facets on enhanced performance of ethanol oxidation"", 《NANOSCALE》, vol. 47, no. 7, pages 20105 - 20116 * |
CUIXIA BI,ET AL: ""Understanding the effect of ultrathin AuPd alloy shells of irregularly shaped Au@AuPd nanoparticles with high-index facets on enhanced performance of ethanol oxidation"", 《NANOSCALE》, vol. 7, no. 47, 16 December 2015 (2015-12-16), pages 20106 - 20107 * |
DONGLIN XIA, ET AL: ""Au–Hemoglobin Loaded Platelet Alleviating Tumor Hypoxia and Enhancing the Radiotherapy Effect with Low-Dose X-ray"", 《ACS NANO》, vol. 14, no. 11, pages 15654 * |
张镇西主编: "《生物医学光子学:诊断、治疗与监测》", 31 August 2017, 西安交通大学出版社, pages: 269 - 270 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Song et al. | Fluorescent carbon nanodots conjugated with folic acid for distinguishing folate-receptor-positive cancer cells from normal cells | |
Pan et al. | Au3+‐Functionalized UiO‐67 Metal‐Organic Framework Nanoparticles: O2•− and• OH Generating Nanozymes and Their Antibacterial Functions | |
Yadav et al. | Functional TiO 2 nanocoral architecture for light-activated cancer chemotherapy | |
Wang et al. | Multi-layered tumor-targeting photothermal-doxorubicin releasing nanotubes eradicate tumors in vivo with negligible systemic toxicity | |
Zhang et al. | Graphene oxide and adenosine triphosphate as a source for functionalized carbon dots with applications in pH-triggered drug delivery and cell imaging | |
Li et al. | Erythrocyte membrane nano-capsules: biomimetic delivery and controlled release of photothermal–photochemical coupling agents for cancer cell therapy | |
CN107158379B (zh) | 核酸适配体修饰核壳型复合材料及其制备方法和应用 | |
CN106362148A (zh) | 一种普鲁士蓝纳米介晶细胞膜包覆修饰方法 | |
CN113933501A (zh) | 一种免疫磁珠及其制备方法和应用 | |
Zhang et al. | Reaction inside a viral protein nanocage: Mineralization on a nanoparticle seed after encapsulation via self-assembly | |
Cao et al. | Graphene quantum dots prepared by electron beam irradiation for safe fluorescence imaging of tumor | |
CN111671897A (zh) | 一种两性离子修饰树状大分子包裹金纳米颗粒/HIF-1α siRNA复合物的制备 | |
WO2020169117A1 (zh) | 具有肝癌靶向和放疗增敏特性的金纳米花及其制备与应用 | |
Nabavifard et al. | Application of dendrimer/gold nanoparticles in cancer therapy: a review | |
CN109112098B (zh) | 促进细胞生长的纳米金核复合物、制备方法及应用 | |
CN112717130A (zh) | 一种Au@AuPd核-壳纳米球及其制备方法、靶向纳米放射增敏剂及其制备方法 | |
CN112755185A (zh) | 一种聚多巴胺包裹的载药二硫化钼纳米片及其制备和应用 | |
CN111517359B (zh) | 一种手性硫化铜超粒子的合成方法 | |
Zhu et al. | Biomimetic gold nanomaterials for biosensing, bioimaging and biotherapy: A mini-review | |
CN110898228B (zh) | 肿瘤自靶向光致异构纳米载体及其制备方法 | |
Cavuslar et al. | pH and molecular weight dependence of auric acid reduction by polyethylenimine and the gene transfection efficiency of cationic gold nanoparticles thereof | |
CN115192708A (zh) | 负载抗肿瘤药物的纳米复合材料、纳米载药体系及制备与应用 | |
CN112870355B (zh) | 一种复合纳米多孔的铂基配位聚合物及其制备方法和应用 | |
CN111203547B (zh) | 小尺寸铝纳米簇材料及其合成方法 | |
CN113940998A (zh) | 一种纳米载氧颗粒及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220929 Address after: 518042 24F, block C, Neo Green Plaza, No. 6009, Shennan Avenue, Tian'an community, Shatou street, Futian District, Shenzhen, Guangdong Applicant after: Shenzhen everything Sensor Technology Co.,Ltd. Address before: 518052-1606, East and west block, Yihai Plaza, 18 Chuangye Road, Nanguang community, Nanshan street, Nanshan District, Shenzhen City, Guangdong Province Applicant before: Shenzhen all things Innovation Group Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210430 |